Aurobindo Pharma Share Price (AUROPHARMA)
Check the latest share price of Aurobindo Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Aurobindo Pharma Stock Performance
Get live Aurobindo Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,135.6Day's Price Range₹1,15552 Week's Low
52 Week's High
₹1,01052-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | -5.72 % |
| 3 Month Return | + 3.46 % |
| 1 Year Return | -8.64 % |
| 3 Year Return | + 114.69 % |
| 5 Year Return | + 49.63 % |
| Market Stats | |
| Previous Close | ₹1,155.20 |
| Open | ₹1,141.00 |
| Volume | 11.33L |
| Upper Circuit | ₹1,270.70 |
| Lower Circuit | ₹1,039.70 |
Aurobindo Pharma Fundamentals & Key Indicators
Check Aurobindo Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹67,394.66 Cr
Return on Equity (ROE)
10.35
PE Ratio (TTM)
19.23
Return on capital employed (ROCE)
11.74
Industry PE ratio
57.39
Beta (LTM)
0.83
P/B Ratio
3.24
Dividend Yield
0.41
PEG Ratio
3.38
Quarterly Earnings Growth YOY
-0.5
EPS (TTM)
54.09
Sector
Pharmaceuticals
Book Value
509.35
Technical Analysis
Bearish
View Technical Analysis
How to invest in Aurobindo Pharma?
Investing in Aurobindo Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Aurobindo Pharma or AUROPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Aurobindo Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Aurobindo Pharma with just a few clicks!
Aurobindo Pharma Stock's Interest Amongst Investors
Aurobindo Pharma Valuation
Track how Aurobindo Pharma P/E has moved over time to understand its valuation trends.
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (19.23x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (27.59x)
December 21, 2023
Today’s Price to Earnings Ratio: 19.23x
Aurobindo Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Aurobindo Pharma.
based on 28 analysts
82.14%
Buy
3.57%
Hold
14.29%
Sell
82.14% of analysts recommend a 'BUY' rating for Aurobindo Pharma. Average target price of ₹1410.5
Source: S&P Global Market Intelligence
Aurobindo Pharma Share Price Target
Get share price movements and forecasts by analysts on Aurobindo Pharma.
Aurobindo Pharma price forecast by 28 analysts
Upside of22.63%
High
₹1930
Target
₹1410.50
Low
₹1100
Aurobindo Pharma target price ₹1410.5, a slight upside of 22.63% compared to current price of ₹1150.2. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:27.56%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:44.66%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Financial Results
Get the annual and quarterly financial summary of Aurobindo Pharma, including revenue, profit, loss and more.
Indices Featuring Aurobindo Pharma Stock
Check stock indices that include Aurobindo Pharma.
Aurobindo Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Aurobindo Pharma.
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -0.58% since last year same period to ₹903.47Cr in the Q4 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 6.82% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.39%.
Read More about Dividends
Aurobindo Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Aurobindo Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 15.33% | 0.00 | |
| Mutual Funds | 18.21% | 0.00 | |
| Retail Investors | 6.61% | 0.00 | |
| Others | 8.03% | 0.00 |
Aurobindo Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Aurobindo Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 67,394.66 | 9.93% | 0.56 | 3,168 | 29,001 | |
| BUY | 14,157.69 | -4.54% | 0.52 | 413 | 2,013 | |
| HOLD | 98,102.78 | 32.58% | 0.64 | 3,854 | 19,547 | |
| BUY | 66,969.38 | 19.17% | 0.53 | NA | NA | |
| BUY | 55,819.29 | 27.46% | 0.56 | 927 | 3,749 |
Aurobindo Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Aurobindo Pharma.
Aurobindo Pharma Named Top Stock Pick by Axis - 05 Jun, 2025
Axis Securities has identified Aurobindo Pharma as a top stock pick, maintaining a Buy rating with a target price of Rs 1,500, indicating a potential upside of 32%.I-Sec Downgrades Aurobindo Pharma Amid Challenges - 30 May, 2025
ICICI Securities downgraded Aurobindo Pharma to 'Add' with a target price of Rs 1,330. The company faces challenges including pricing competition and temporary production halts, but expects growth from new product launches in Europe.Aurobindo Pharma Expands Biopharma Business in Europe - 29 May, 2025
Aurobindo Pharma's wholly owned subsidiary, Curateq Biologics, has established a new subsidiary, CuraTeQ Biologics B.V., in the Netherlands to enhance its biopharma operations in Europe. Despite this expansion, the company's consolidated net profit fell by 0.6% in Q4 FY25.Citi Downgrades Aurobindo Pharma Amid Growth Concerns - 28 May, 2025
Citi has downgraded Aurobindo Pharma to 'Sell' and reduced its target price to ₹1,100, highlighting concerns over flattening US growth and margin pressures. Despite a 10.6% revenue increase in Q4FY25, adjusted EBITDA fell short of expectations, prompting an 8% cut in EPS estimates for FY26-27. Analysts remain divided, with some maintaining 'Buy' ratings, but overall sentiment appears cautious.Aurobindo Pharma Q4 Results Show Mixed Performance - 26 May, 2025
Aurobindo Pharma's Q4 results reveal a slight profit dip to ₹903 crore despite an 11% revenue increase to ₹8,382 crore. Full-year PAT rose 10%.Aurobindo Pharma Launches Leadership Development Initiative - 16 May, 2025
Aurobindo Pharma's subsidiary, Apitoria, has launched the Auro Astra leadership development program in collaboration with IMT Hyderabad, aimed at enhancing middle management skills through immersive learning.Aurobindo Pharma Shares Rise 3% on Market Optimism - 13 May, 2025
Aurobindo Pharma shares increased by 3% as investors reacted positively to expectations that US President Trump's executive order would minimally affect US generics market.Aurobindo Pharma Upgraded to Buy Rating - 12 May, 2025
Motilal Oswal has upgraded Aurobindo Pharma to a Buy rating with a target price of ₹1,360, highlighting the company's strategic investments and diversified generics portfolio. The firm anticipates significant contributions from the Penicillin G project and ongoing growth in the US generics market despite recent stock corrections.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 17.81% to 18.21% in Mar 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 11 quarters, 5.79K Cr → 8.51K Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 817.38 Cr → 903.47 Cr (in ₹), with an average increase of 4.9% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 16.4%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 53.9%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Mar 2025 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.69% to 6.61% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, AUROPHARMA stock has moved down by -5.7%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.29% to 15.33% in Mar 2025 quarter
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹8,381.12Cr as on March 2025 (Q4 FY25)
Net Profit: ₹902.83Cr as on March 2025 (Q4 FY25)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | K Ragunathan |
| E-voting on shares | Click here to vote |
Mutual Funds that own Aurobindo Pharma
Check out the Mutual Funds with significant holdings in Aurobindo Pharma.
FAQs
What is Aurobindo Pharma share price today?
Aurobindo Pharma share price today stands at ₹1150.2, Open: ₹1141, Previous Close: ₹1155.2, High: ₹1155, Low: ₹1135.6, 52 Week High: ₹1592, 52 Week Low: ₹1010.
What is today's traded volume of Aurobindo Pharma?
Today's traded volume of Aurobindo Pharma is 11.33L. Which means that 11.33L shares of Aurobindo Pharma were bought and sold on the stock market during today's trading session.
What is Aurobindo Pharma's market cap today?
Today's market capitalisation of Aurobindo Pharma is ₹67,394.66 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Aurobindo Pharma?
Aurobindo Pharma’s 52 week high is ₹1592 and 52 week low is ₹1010. The current share price of Aurobindo Pharma is ₹1150.2, which is -27.75% down from its 52 week high and 13.88% up from its 52 week low.